Urogen Pharma Ltd
URGN
View Detailed Chart
20.620USD
+0.150+0.73%
Close 11/03, 16:00（ET）Quotes delayed by 15 min
952.63MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.73%
5 Days
-1.10%
1 Month
+18.51%
6 Months
+79.15%
Year to Date
+93.62%
1 Year
+69.02%
View Detailed Chart
TradingKey Stock Score of Urogen Pharma Ltd
Currency: USD Updated: 2025-11-03Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Urogen Pharma Ltd's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
8
analysts
Buy
Current Rating
33.750
Target Price
+64.88%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Urogen Pharma Ltd Highlights
StrengthsRisks
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 40.46% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 90.40M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 90.40M.
Undervalued
The company’s latest PE is -6.74, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 45.30M shares, decreasing 13.24% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 1.90K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.24.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Urogen Pharma Ltd Info
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Ticker SymbolURGN
CompanyUrogen Pharma Ltd
CEOMs. Elizabeth A. (Liz) Barrett
Websitehttps://www.urogen.com/
Related Instruments
+0.95%
-1.78%
-2.37%
-1.19%
+0.44%
+0.04%
+1.56%
-1.27%
-3.65%
-1.76%
+3.54%
-0.31%
-0.87%
+0.83%
-1.58%
-2.50%
-2.09%
-1.56%
0.00%
-0.67%Popular Symbols
